United Therapeutics Corporation (NASDAQ:UTHR) Q3 2023 Earnings Call Transcript November 1, 2023
United Therapeutics Corporation beats earnings expectations. Reported EPS is $5.38, expectations were $4.88.
Operator: Good morning, and welcome to the United Therapeutics Corporation Third Quarter 2023 Earnings Webcast. My name is Rocco, and I will be your conference operator today. All participants on the call portion of this webcast will be in a listen-only mode until the question-and-answer portion of this earnings call. [Operator Instructions] Please note, this call is being recorded. I will now turn the webcast over to Dewey Steadman, Head of Investor Relations at United Therapeutics. Please go ahead.
Dewey Steadman: Thank you, Rocco, and good morning, everyone. It’s my pleasure to welcome you to the United Therapeutics third quarter 2023 earnings webcast. Accompanying me today are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Michael Benkowitz, our President and Chief Operating Officer; James Edgemond, our Chief Financial Officer and Treasurer; Pat Poisson, our Executive Vice President of Technical Operations; and Dr. Leigh Peterson, our Executive Vice President of Product Development & Xenotransplantation. Remarks today will include forward-looking statements, representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially.
Our latest SEC filings, including Forms 10-K and 10-Q contain additional information on these risks and uncertainties, and we assume no obligation to update these forward-looking statements. Also today’s remarks may discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making, or to suggest that any products are safe and effective during any unapproved or investigational uses. Full prescribing information for our products are available on our website. Note that, Pat Poisson and I will be presenting in a fireside chat session in one-on-one meetings at the 2023 UBS Biopharma Conference on November 8.
And Martine Rothblatt will participate in a fireside chat and one-on-one meetings at the JPMorgan Healthcare Conference in early January. Now I’ll turn the call over to Dr. Rothblatt for an overview of our third quarter 2023 financial results and the business activities of United Therapeutics. Martine?
Martine Rothblatt: Thank you, Dewey. First off, I’d like to congratulate our team as we had an amazing third quarter for the second quarter in a row. I’m thrilled to report our highest quarterly revenue ever along with double-digit revenue growth as compared to the third quarter of 2022. On top of that, our operational efficiency in the third quarter resulted in one of our highest quarterly net incomes and earnings per share ever. At United Therapeutics, we’re uniquely positioned for three waves of growth with a profile that’s unique in biotechs. Our first wave of growth will come through our existing commercial business led by Tyvaso and pulmonary hypertension associated with interstitial lung disease or PH-ILD. We continue to post solid growth in our current business with record quarterly revenue and patients on therapy for treprostinil products as a whole.
Our growth in PH-ILD and continue leadership in pulmonary arterial hypertension or PAH has led to nebulized Tyvaso and Tyvaso DPI products combining to become the most prescribed prostacyclin therapy in the U.S. Michael will go into detail on our commercial business later in this call. We believe this growth will continue in the near term and we expect at least a $4 billion annual revenue run rate by mid decades doubling our revenue from 2022 and implying a double-digit compound annual growth rate. Our second wave of growth will come from our near-term pipeline led by the TETON program in pulmonary fibrosis and ralinepag in PAH. These two products, if approved, could lead our revenue to double again to $8 billion by the end of the decade. I will provide updates on the TETON and ralinepag program shortly.
Of course, both of our first and second waves of growth are subject to clinical trial outcomes, regulatory approvals, new competitive entrants [ph], and the potential impacts of the Inflation Reduction Act. But we feel good about our prospects for meeting these revenue aspirations. Our third wave of sustainable growth will come through the development, manufacturer and widespread use of manufactured organs and organ technologies to provide a solution to patients experiencing end stage kidney, lung, heart, and liver disease. Moving to our near-term pipeline and second wave of growth, we have two key registration programs underway, TETON for pulmonary fibrosis, and ralinepag an oral therapy for Group 1 PAH. TETON now consists of three registration studies, TETON 1 and TETON 2 for idiopathic pulmonary fibrosis or IPF and now TETON PPF for progressive pulmonary fibrosis.
We believe IPF represents a 100,000 patient opportunity in the United States with only two approved therapies that just slow lung function decline. Both TETON 1 and TETON 2 are enrolling patients. And at this time, we are aiming for full enrollment in both studies with 576 patients each by the end of 2024. Likewise, we believe PPF represents up to a 60,000 patient opportunity in the U.S., which is distinct from IPF. One of the two FDA approved IPF therapies is also approved for PPF and liking IPF it only slows the decline of lung function in these fragile patients. As we reported earlier this week, the TETON PPF study has dosed its first patient. We expect this trial to enroll 698 patients. We believe there is a relatively high probability of success in the three TETON studies based on an IPF subset of the increased study of nebulized Tyvaso in PH-ILD patients.
Unlike the two IPF therapies on market, nebulized Tyvaso in a safety endpoint showed in an improvement of lung function in the subset of patients that had IPF along with pulmonary hypertension. We’re also encouraged by a recent review by the Data Safety Monitoring Committee of data from 550 patients in the TETON 1 and TETON 2 studies. The committee completed a routine unblinded safety review of data from these patients and unanimously recommended continuation of both trials without modification [ph]. Our advanced outcome study of ralinepag in Group 1 PAH continues to enroll patients. And at this time we are targeting completion of the study in 2025. Ralinepag is a next generation selective and potent prostacyclin receptor agonist, and we are developing it as a once daily oral therapy for PAH.
We believe ralinepag in once daily dosing sustained release profile and titratability could position it favorably against the other oral prostacyclin receptor agonist as well as other therapies currently available for PAH patients. Ralinepag provides 24-hour coverage with 6.5x to 10x the potency of the other oral prostacyclin receptor agonist on the market and ralinepag demonstrated more than 20% improvement in pulmonary vascular resistance in Phase 2 studies. That’s close to the improvement observed in intravenous epoprostenol. Long-term Phase 2 open-label studies of ralinepag also showed sustained improvement in six-minute walk distance. We are pleased to announce that the Data Safety Monitoring Committee for the advanced outcome study met for the fourth time last month and unanimously recommended the continuation of the trial without modification after evaluating unblinded data from 510 patients enrolled in the study.
We are targeting 700 patients to a 1,000 patients in the study, depending on the pace of accruing clinical worsening events. Moving to our organ programs, we have been developing several investigational approaches using different technologies with different organs. The first is our ex-vivo lung perfusion service or EVLP, which has led to over 350 lives saved with lungs that have undergone EVLP. We’re also developing xenotransplantation products consisting of hearts and kidneys. Finally, we’ve been working on 3-D printing and regenerative medicine technologies to develop manufactured lungs and kidneys. At United Therapeutics, we always want multiple shots on goal. To that end, we recently acquired privately held IVIVA Medical based out of Woburn, Massachusetts.
IVIVA’s core technology is an engineered kidney implant that mimics native kidney elements with a simple architecture to achieve implantable, durable blood purification much like a native kidney. IVIVA’s kidney is seated with a patient’s own cells, eliminating the need for immunosuppression. Also, earlier this week we announced an agreement to acquire publicly traded Miromatrix Medical, a company focused on ending the waiting list for organ transplantation. Miromatrix utilizes an organ manufacturing platform that consists of decellularized porcine organs that are then cellularized with cells derived from non-transplantable donor human organs. These organ constructs are intended to replace some of the functionality of human organs using standard organ transplantation techniques and immunosuppression regimens.
Miromatrix has three key programs that would broaden our existing manufactured organ pipeline. MiroliverELAP, which is ex-vivo or outside the body and intended to provide temporary external liver dialysis for acute liver failure. Mirokidney, a fully-implanted kidney and Miroliver, a fully-implantable liver. Moving to Xenotransplantation. We continue to work with the FDA on a clinical path forward. We’re underway with what we call pivotal preclinical studies in baboons at the request of the FDA. Specifically, for our 10-gene program we expect the last preclinical xenokidney transplant to occur in early 2024. After collecting the data we’ll meet with the FDA to discuss the IND and clinical protocol for human studies for our 10-gene xeno organs.
In parallel with the pivotal preclinical studies, we’re wrapping up construction of our clinical stage designated pathogen-free facility or DPF, in Virginia. We expect the facility to begin receiving pigs in early 2024 and for the facility to grow its population through the balance of 2024 in preparation for clinical studies in humans for both xenokidneys and xenohearts. Behind our Xenotransplantation programs, our manufactured lungs now in large mammal testing by our North Carolina-based regenerative medicine team, and behind that our 3D printed autologous lungs by our New Hampshire-based organ manufacturing group using technologies from our partner, 3D Systems. We look forward to sharing more detail on these programs as they progress towards clinical studies.
I’m thrilled that we’re in such a great position at United Therapeutics. We have a solid commercial business posting record results with continued strong growth ahead, a pipeline of novel therapies that could again double our revenues by the end of the decade. And on top of all of that we have a long-term plan to address one of the largest, critical, unmet medical needs while helping our patients, employers and the employees and shareholders all succeed. I’ll now turn the call over to our President, Michael Benkowitz, who will give an overview of our commercial performance and progress for our near-term goal of a $4 billion annual revenue run rate by mid-decade. Mike?
Michael Benkowitz: Thanks, Martine, and good morning, everyone. As Martine noted, today, we reported our highest revenue quarter ever at $609 million, up 18% from the third quarter of 2022. We saw meaningful growth for each of the Tyvaso franchise, Remodulin, Orenitram and Unituxin. With respect to Orenitram, we saw revenue of $92 million during the quarter, which was up 5% from the prior year. This growth reflects increases to both patient growth and average dose. In the third quarter, following the publication of two peer-reviewed manuscripts, we are also able to commence education efforts by our field-based teams on the EXPEDITE protocol, which is based on our rapid Remodulin titration and transition to Orenitram study, allowing patients to get to higher doses of Orenitram quicker and with less side effects than starting Orenitram de novo.
Remodulin revenue of $131 million was up 15% from last year, reflecting both U.S. patient growth from the third quarter of 2022 as well as an increase in international sales from the same period last year. Patients who use our Remunity Pump now make up more than 50% of subcutaneous Remodulin patients in the U.S. compared to under 10% at the same period just last year. Remodulin continues to be the Number 1 prescribed parenteral therapy for PAH in the U.S. Moving to Unituxin; we saw revenue of $51 million, which was up 11% from the prior year quarter. This growth was driven by an increase in U.S. sales and includes a modest inventory build at our U.S. distributor. Finally, Tyvaso; We saw revenue of $326 million for Tyvaso DPI and nebulized Tyvaso combined, which was up 26% from the prior year quarter and was the highest Tyvaso revenue quarter ever.
This growth was principally driven by new patients on therapy. This performance reflects the rapid uptake of Tyvaso DPI among physicians and patients, as well as continued expansion into the PH-ILD market. We saw the highest number of referrals and patient starts for the combined Tyvaso business during the quarter. I’m proud to report that Tyvaso is now the Number 1 prescribed prostacyclin treatment in the U.S. and remains the only approved therapy for PH-ILD. Regarding Tyvaso DPI inventory, the first phase of process improvements and new equipment at our partner MannKind that went online in June has meaningfully helped to expand the supply of Tyvaso DPI. These enhancements, coupled with a further expansion that will come online next year have us well positioned to provide ample supply of Tyvaso DPI moving forward.
We’re now working to drive growth in PH-ILD, where Tyvaso remains the only approved product, as I mentioned before. We have been increasing the size of our field-based teams over the last 12 months, adding medical science liaisons, regional nurse specialists, and more recently sales representatives and reimbursement specialists to our team. With this expansion, we’re able to both reach more prescribers and importantly focus on driving depth within these prescribers. And we’ve already made great progress. On the last earnings call, I mentioned that we’ve more than doubled the number of Tyvaso prescribers since the PH-ILD approval in 2021, and maintain depth, defined as three or more patients per prescriber, at about 40% of these prescribers.
Peeling that back a little bit, about 50% of the growth in those total prescribers are true ILD prescribers, which means we’re now starting to see these physicians begin to treat the disease rather than refer these patients into the PAH clinics. Depth within our true ILD treaters is also coming along nicely with about 20% of those prescribers having three or more patients on Tyvaso. Our recent sales force expansion will allow us to continue to lean into the ILD physicians, particularly in the community setting. While Tyvaso DPI has been a tremendous – has been a source of tremendous growth since we launched it last year, we continue to appreciate the value of nebulized Tyvaso in our portfolio. Some physicians and patients continue to prefer the nebulizer because of its profile or for reimbursement reasons.
In addition, we’re aware that some pulmonologists prefer to start and titrate their PH-ILD patients using the nebulizer before switching to Tyvaso DPI. This allows more precise titration in one breadth increments compared to the three-breath equivalent increments of Tyvaso DPI. We expect this platform strategy to become a competitive advantage over other potential DPI products should they reach the market. Before we move to the Q&A, I want to take a moment to address some questions we’ve received around potential competition and reiterate our confidence that we’re well positioned for growth in the near-term with our current commercial portfolio. Questions have centered primarily around sotatercept and a potential inhaled treprostinil competitor.
First, with respect to sotatercept; it’s important to note that it will not be indicated for PH-ILD if approved next year, and therefore will not be a factor in the source of our most recent growth and expected near-term growth. In Group 1 PAH, where it will be indicated if approved, it appears this drug will be a nice addition to the PAH armamentarium. But based on the clinical data and our experience with new agents entering the space, it will be an addition, not a replacement, for existing therapies. And therefore, we remain extremely confident in the durability of our PAH business. Targeting multiple pathogenic pathways is considered the current standard of care for PAH. This mirrors therapy for other serious conditions that result from multiple pathways of pathogenesis like cancers, heart failure and some viral infections.
In fact, sotatercept was studied only in combination with other PAH products, including 70% of patients on concomitant prostacyclins or prostacyclin analogs including our treprostinil products. We believe the convenience of Tyvaso DPI allows physicians to easily, relatively speaking cover the prostacyclin pathway for those patients not already on a prostacyclin. And if the addition of sotatercept helps patients live longer, that’s phenomenal for the patients, of course and likewise, benefits us from a revenue standpoint because patients will be on our medicines longer. Moving to the other inhaled treprostinil that could reach the market, we believe we have a preferred product with Tyvaso DPI. Tyvaso DPI demonstrated 98% patient satisfaction in the pre-study and has now been prescribed to more than 4,000 patients, a clear demonstration of patient physician interest and our DPI format.
Tyvaso DPI is differentiated from its potential competitor because of its simple, easy-to-use inhaler that patients just open load and inhale with only one breath per cartridge four times a day. Tyvaso DPI’s low-flow profile also facilitates treprostinil delivery deep and consistently into the lungs with generally only title breathing required to actuate a dose. On top of that, the Tyvaso DPI inhalation device requires no cleaning and patients can hold the inhaler in an actual position when using the device. So to wrap up, we’re extremely proud of our record performance this quarter, and we think we’re in the early stages of sustainable growth for our current commercial portfolio as we continue to make in-roads with PH-ILD prescribers and our base business in PAH will continue to be appreciated by prescribers and patients alike.
So with that, Martine, I’ll turn it back over to you for the Q&A.
Martine Rothblatt: Thanks Mike. I hope everyone can tell that United Therapeutics is a truly compelling investment with a strong cash-generating commercial business supporting novel R&D efforts in rare lung disease, coupled with the revolutionary potential for our organ manufacturing programs. Operator, let’s start the Q&A session.
See also 15 Best US Cities for Public Transportation and 35 Best Places To Visit in the USA in October.
To continue reading the Q&A session, please click here.